Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved treatments for IPF but have limited efficacy and their mechanisms of action are poorly understood. Here we have exam...
Saved in:
Main Authors: | KM Roach (Author), E Castells (Author), K Dixon (Author), S Mason (Author), G Elliott (Author), H Marshall (Author), MA Poblocka (Author), S Macip (Author), M Richardson (Author), L Khalfaoui (Author), P Bradding (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024) -
Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023) -
Individual Freedom in the Initial Response to Covid-19
by: Salvador Macip, et al.
Published: (2022) -
Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
by: José M. Serra López-Matencio, et al.
Published: (2021) -
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018)